


In the Claims

This listing of the claims reflects the claims as currently pending in the application.

1. (original) A method of inhibiting a transforming growth factor $\beta 2$ (TGF $\beta 2$) comprising contacting said TGF $\beta 2$ with a nucleic acid ligand of TGF $\beta 2$.
2. (original) The method of claim 1, wherein the nucleic acid ligand of TGF $\beta 2$ is a ligand comprising a ligand having a nucleotide sequence selected from the group consisting of SEQ ID NOS:21-87, 89, 91-93, 109, 111, 114-116, 118-121, 129, 131, 138, 140, 144, 146-181, 184-189, 192, and 193.
3. (original) The method of claim 1 wherein said nucleic acid ligand is conjugated to polyethylene glycol (PEG).
4. (original) The method of claim 3 wherein said PEG has a molecular weight of about between 10-80 K.
5. (original) The method of claim 3 wherein said PEG has a molecular weight of about 20-45 K.
6. (original) The method of claim 1 wherein said ligand is



LIGAND=
rGrGrArGrGfUfUrAfUfUrAfCrArGrArGfUfCfUrGfUfUrArGfCfUrGfUrAfCfUfCfC-3'-3'-dT
(SEQ ID NO:115), wherein rG is 2'OH G, rA is 2'OH A, fU is 2'F U and fC is 2'F C.

covalently linking said nucleic acid ligand to a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound to form a Complex, and administering said Complex to said patient, whereby said nucleic acid ligand is targeted to a site in a patient comprising TGF β 2.


8. (original) The method of claim 7, wherein the nucleic acid ligand of TGFβ2 is a ligand comprising a ligand having a nucleotide sequence selected from the group consisting of SEQ ID NOS:21-87, 89, 91-93, 109, 111, 114-116, 118-121, 129, 131, 138, 140, 144, 146-181, 184-189, 192, and 193.

9. (original) The method of claim 7 wherein said nucleic acid ligand is conjugated to polyethylene glycol (PEG).

10. (original) The method of claim 9 wherein said PEG has a molecular weight of about between 10-80 K.

11. (original) The method of claim 9 wherein said PEG has a molecular weight of about 20-45 K.

12. (original) The method of claim 7 wherein said ligand is



wherein

$\text{X} = \text{PEG}$, and

LIGAND=

rGrGrArGrGfUfUrAfUfUrAfCrArGrArGfUfCfUrGfUfUrArGfCfUrGfUrAfCfUfCfC-3'-3'-dT (SEQ ID NO:115), wherein rG is 2'OH G, rA is 2'OH A, fU is 2'F U and fC is 2'F C.

13. (original) A method for treating a TGF β 2-mediated pathological conditions comprising administering a nucleic acid ligand capable of binding to TGF β 2 to a patient in need thereof.


14. (original) The method of claim 13, wherein the nucleic acid ligand of TGF β 2 is a ligand comprising a ligand having a nucleotide sequence selected from the group consisting of SEQ ID NOS:21-87, 89, 91-93, 109, 111, 114-116, 118-121, 129, 131, 138, 140, 144, 146-181, 184-189, 192, and 193.

15. (original) The method of claim 13 wherein said nucleic acid ligand is conjugated to polyethylene glycol (PEG).

16. (original) The method of claim 15 wherein said PEG has a molecular weight of about between 10-80 K.

17. (original) The method of claim 15 wherein said PEG has a molecular weight of about 20-45 K.

18. (original) The method of claim 13 wherein said ligand is



wherein

X=PEG, and

LIGAND=
rGrGrArGrGfUfUrAfUfUrAfCrArGrArGfUfCfUrGfUfUrArGfCfUrGfUrAfCfUfCfC-3'-3'-dT
(SEQ ID NO:115), wherein rG is 2'OH G, rA is 2'OH A, fU is 2'F U and fC is 2'F C.